As of November 6, 2026, Acro Biomedical Co., Ltd. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 2, 2026 (Form 8-K, September 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Acro Biomedical Co., Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Acro Biomedical Co., Ltd. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-02. Every row below is cited to the filing it comes from, and this page adds each new change as Acro Biomedical Co., Ltd. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-02 | Reported | not named in the filing | 8-K, 2026-09-02 |
Selling to them or working with them? See who runs Acro Biomedical Co., Ltd. now and the warning signs.
Free to see. No signup.
Watch Acro Biomedical Co., Ltd.
Get an email when Acro Biomedical Co., Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Acro Biomedical Co., Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Acro Biomedical Co., Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Acro Biomedical Co., Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on Acro Biomedical Co., Ltd.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Acro Biomedical Co., Ltd., with the record behind each one.
Find candidates like senior executive at Acro Biomedical Co., Ltd.Every change, in the filing's words
Reported
On September 2, 2026, Yu-Ting, Su resigned as director, chairman and chief executive officer of the Company, effective upon the appointment of a successor.
- Ms. Su's resignation did not result from any disagreement with the Company.
- On September 2, 2026, the Company's board of directors appointed Shao-Hsiang Shih as a director and as the Company's chairman, effective on September 2, 2026.
- Mr. Shao-Hsiang Shih has served as Director of Administrative Management at Century Publishing Co. since 2020.
- From 2010 to 2020, Mr. Shih served as Director of Education Management at Century Publishing Co. Prior to joining Century Publishing Co., he served as Director of Education Management at Century Education Center from 2000 to 2010.
- Mr. Shih graduated from the Department of Statistics at National Taipei University in 2003.
- He received a Master's Degree from the Graduate Institute of Buddhist Studies at Fo Guang University in 2018.
- Since 2018, Mr. Shih has pursued doctoral studies at the Graduate Institute of Eastern Humanistic Thought at Huafan University.
- On September 2, 2026, the Company's board of directors appointed Jing-Zhou Chen as chief executive officer and chief financial officer, effective on September 2, 2026.
- Mr. Nick (Jing-Zhou) Chen has served as Chief Executive Officer and founder of Dream Born Co., Ltd. since March 2025, where he is responsible for the company's overall strategy, operations, business development and technology platform initiatives.
Tools for this story
Each opens in a new tab, filled in for Acro Biomedical Co., Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.